LLY remains above its 20‑day moving average with a bullish MACD crossover and earnings that beat expectations, supporting a fair‑value upside of roughly 9%. The stock appears undervalued given its robust pipeline and dividend yield.

Cathie Wood’s new stake and strong earnings momentum keep sentiment firmly bullish on LLY despite emerging competition. The broader GLP‑1 hype is driving inflows that reinforce upside potential.

While LLY’s fundamentals stay solid, Viking Therapeutics’ novel weight‑loss candidate introduces a material long‑term competitive risk. Consequently, the outlook is balanced, meriting a neutral stance.

Technical indicators show LLY’s RSI at 58 and a recent MACD bullish crossover, accompanied by a 12% volume surge on earnings day. These data points generate a bullish signal with confidence around 82%.